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OBJECTIVES The goal of this study was to examine the outcomes of percutaneous coronary interventions
(PCI) and the predictors for restenosis after cardiac transplantation.
BACKGROUND The role of PCI as definitive therapy for allograft coronary disease (ACD) remains
contentious.
METHODS Between January 1, 1990 and December 31, 2000, 62 patients (1.5 to 15.5 years after
transplant) underwent 151 procedures resulting in PCIs of 219 lesions. Follow-up after PCI
angiography was usually obtained at three and six months, then yearly. Repeat PCI was
routinely done to lesions with 60% restenosis.
RESULTS The primary procedural success was 97%. Repeat PCI occurred in 74 of 219 lesions (34%);
PCI-related mortality was 2.6% (4 of 151). The freedom from re-PCI (of same vessel site)
was 75% at six months, 65% at one year, and 57% at four years. The freedom from restenosis
was 95% at one month, 81% at three months, and 57% at six months. Multivariate predictors
of freedom from restenosis were the use of stents, higher anti-proliferative immunosuppres-
sant dose, and an era effect. In the setting of one-vessel disease at first PCI, the two-year
freedom for ACD death or graft loss was 74%, compared with 75% for two-vessel and 27%
for three-vessel disease (p  0.009).
CONCLUSIONS Despite the increasing effectiveness of PCI for localized ACD, the survival after development
of advanced ACD remains poor. Stents appear to increase effectiveness of PCI for ACD, but
other factors in the current era contribute to improved outcomes. (J Am Coll Cardiol 2004;
43:1973–81) © 2004 by the American College of Cardiology Foundationt
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vllograft coronary disease (ACD) remains a predominant
arrier to long-term survival after cardiac transplantation.
here is a steady and linear risk of developing angio-
raphically visible ACD from year one, so that by five
ears, over 50% of cardiac transplant recipients will have
ome disease (1). Beyond five years, the risk of developing
ngiographically visible severe disease increases propor-
ionally, so that 29% of patients will have significant
isease by nine years post-transplant (2). The risk of
eath from ACD also rises steadily after transplant and
ccounts for nearly 25% of all deaths between years 1 and
0 (1). Even discrete lesions 40% in the proximal or
id-major epicardial vessels, if left untreated, can lead to
ortality rates exceeding 50% by three years (3). Once
atients develop three-vessel or severe ACD, their risk of
ardiac events (death or retransplantation) is substantial
ith the highest risk within one year of diagnosis (3).
Unfortunately, treatment of advanced disease is lim-
ted. Retransplantation is not an option for all, given the
imited donor pool, and the results of bypass surgery for
From the *Department of Medicine, Division of Cardiovascular Disease, University
f Alabama at Birmingham, Birmingham, Alabama; †Department of Medicine,
irmingham VA Medical Center, Birmingham, Alabama; and ‡Department of
urgery, Division of Cardiovascular Surgery, University of Alabama at Birmingham,
irmingham, Alabama.
Manuscript received March 3, 2003; revised manuscript received January 16, 2004,sccepted January 27, 2004.his condition are generally poor (4). Percutaneous trans-
uminal coronary angioplasty (PTCA) is an established
odality for treatment of focal native coronary artery
isease (CAD) and ACD, but its value in diffuse disease
s not well established.
Numerous studies have examined the procedural effi-
acy of PTCA post-transplant, but most involve small
30 patients) single-center experiences with few PTCA
rocedures (average 40 to 50) (4 – 6). From these studies,
t appears that the initial procedural success is high (90%
o 98%), and the incidence of restenosis is 30% to 100%
or PTCA alone and 14% to 56% with stents (7–9).
owever, in many of these studies, the definitions for
estenosis and the duration of follow-up differ, resulting
n considerable variability in reported results. Short-term
urvival post-procedure is generally good with a one- to
wo-year mortality of 17% to 35% (4,6,9). Unfortunately,
isk factors analyses for restenosis (one study) and longer-
erm survival data are generally lacking.
The purpose of the present analyses was to examine in a
arge series of post-transplant percutaneous coronary inter-
entions (PCI) the outcomes of these procedures for local-
zed disease, including primary procedural success, resteno-
is, and reintervention rates. We also sought to define the
redictors for restenosis and gain insight into the potential
alue of PCI as part of an overall strategy to prolong graft
urvival after the development of ACD.
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atients. All patients transplanted at the University of
labama at Birmingham who had a PCI (PTCA alone,
TCA with stent) between January 1, 1990 and December
1, 2000 were included in this analysis. Thus, this study
omprised 62 patients who underwent 151 procedures (trips
o the angioplasty suite) resulting in PCI of 219 lesions.
ngiographic follow-up was available in 174 (79%) of these
rocedures; 45 procedures had no angiographic follow-up
ecause of death (10), retransplantation (7), primary proce-
ural failure (6), or other (10).
ngiography. Measurements of lesions were made with
lectronic calipers, and minimal luminal diameters (MLDs)
ere determined. A calibration factor was determined as the
atio of the measured diameters of the diagnostic or guiding
atheters to their known dimensions. The quantitative
imensions were then calculated as the product of the
easured dimension by the calibration factor. The view
ith the worst stenosis was used for the initial lesion
tenosis calculation. Whenever possible, the same angio-
raphic views were used in follow-up films for restenosis
alculations. The percent diameter stenosis was calculated
s: (reference diameter  MLD)/(reference diameter) 
00. Procedural success was defined as a 50% residual
tenosis and restenosis defined as 50% stenosis at the
ngioplasty site on follow-up angiography. Patients had
nnual coronary angiography according to current guide-
ines at the University of Alabama at Birmingham.
ollow-up angiography to determine the need for reinter-
ention was usually obtained at three and six months, then
early. Repeat PCI was routinely applied to vessel sites with
60% restenosis.
emographics and data collection. The demographic
ariables collected on all patients included age, race, gender,
eight, weight, body mass index, time since transplant,
retransplant heart disease, and time since initial diagnosis
f ACD. Clinical variables collected included detailed
istory of immunosuppressants at time of procedure includ-
ng type, dose, level (if appropriate), and duration of use
efore procedure; rejection history including total number
nd number of treated rejections since transplant and within
ix months of procedure; lipid levels closest to time of
rocedure; as well as the presence of diabetes mellitus,
ypertension, history of tobacco use, and cytomegalovirus
Abbreviations and Acronyms
ACD  allograft coronary disease
AP  anti-proliferative
CAD  coronary artery disease
MLD  minimal luminal diameter
MMF  mycophenolate mofetil
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary angioplastyerology and infections. A detailed account of non- tmmunosuppressant medications at time of procedure was
lso collected including use of angiotensin-converting en-
yme inhibitors, angiotensin 2 receptor blockers, calcium
hannel blockers, and HMG-CoA reductase inhibitors.
rocedural variables collected included percent stenosis,
esion location, stent use, and procedural medication use
ncluding thienopyridines (ticlid/plavix), aspirin, glycopro-
ein IIb/IIIa antagonists, and heparinoids.
tatistical analyses. Kaplan-Meier and three-phase para-
etric analysis in the hazard function domain (11) were
sed to examine the event restenosis (defined as recurrence
f 50% or greater stenosis after a “successful” PCI [50%
tenosis on follow-up angiogram]) and death or graft loss
ue to ACD. Risk factors for restenosis were explored by
ultivariable hazard function analysis. The variables en-
ered into the analysis are listed in the Appendix Risk
actors were retained in the model if the p value was 0.05.
ollow-up was restricted to eight months after PCI.
ESULTS
emographics. Baseline demographic, clinical, and proce-
ural variables are represented in Table 1. Mean time from
able 1. Demographic and Procedural Characteristics
emographic characteristics
Number of patients 62
Mean age at first PTCA, yr (SD) 54  13
Male gender, n (%) 47 (76)
Race, n (%)
Caucasian 55 (76)
African American 7 (11)
Weight at first PTCA, kg (SD) 88  17
linical characteristics
Cholesterol profile
Total cholesterol, mg/dl (SD) 223  66
Triglycerides, mg/dl (SD) 259  184
Low-density lipoprotein, mg/dl (SD) 126  44
High-density lipoprotein, mg/dl (SD) 44  13
Immunosuppression*
Mycophenolate mofetil, % 12
Azathioprine, % 69
Cytoxan, % 12
Prednisone only, % 6
Other medications
Beta-blockers, % 19
Angiotensin-converting enzyme inhibitors, % 38
Calcium-channel blockers, % 74
Aspirin, % 75
rocedural characteristics
Total number of procedures 151
Total number of interventions 219
PCI 1990–1996, n (%) 85 (62)
PCI 1997–2000, n (%) 66 (44)
Stent, n (%) 84 (38)
No stent, n (%) 135 (62)
Periprocedural use of GP IIb/IIIa antagonists, n (%) 14 (9)
Periprocedural use of ticlid/plavix, n (%) 69 (46)
Only four patients were not on calcineurin antagonist (cyclosporine or prograf).
GP  glycoprotein; PCI  percutaneous coronary intervention; PTCA 
ercutaneous transluminal coronary angioplasty.ransplant to first PCI was 7.2 years (range, 1.5 to 14.5
y
w
p
m
P
9
a
a
c
1
m
fi
r
f
m
f
R
a
p
s
“
t

p
r
s
m
t
a
d
h
g
f
p
A
1
6
c
F
p
a
2
h
i
r
a
m
w
m
c
F
p
o
1975JACC Vol. 43, No. 11, 2004 Benza et al.
June 2, 2004:1973–81 PTCA and Allograft Vasculopathyears). Mean time from first PCI to follow-up angiography
as two months (range, 1.3 to 8 months) with 75% of
rocedures having follow-up angiograms between 5.5 to 8
onths.
rocedural outcomes. Primary procedural success was
7% (213 of 219 lesions). Periprocedural mortality was low
t 2% (4 of 151 procedures). There were no incidences of
cute stent thrombosis. Primary re-PCI for restenosis oc-
urred in 34% of initially treated lesions (74 of 219). Figure
depicts the freedom from re-PCI over time. As noted, the
ajority of the repeat procedures were performed within the
rst year after the primary procedure. The freedom from
e-PCI was 75% at six months, 65% at one year, and 57% at
our years. There was a 95% freedom from restenosis at one
onth, 81% freedom at three months, and only a 57%
reedom by six months (Fig. 2).
isk factor analysis for restenosis. Multivariate risk factor
nalysis of potential risk factors (demographic, clinical, and
rocedural variables) for restenosis demonstrated only four
ignificant factors (Table 2). The use of stents, higher dose
anti-proliferative” (AP) immunosuppressant drugs (aza-
hioprine 1 mg/kg/day or mycophenolate mofetil [MMF]
3 g/day), and having PCI after 1997 were negative
redictors of restenosis. Positive risk factors for developing
estenosis included having a PCI before 1997 and a more
evere initial stenosis at time of PCI.
igure 1. Kaplan-Meier depiction of the event re-percutaneous coronary
lotted as the smooth curve. Error bars and parametric confidence limits
f the plot.The impact of stents was apparent within the first few months after a PCI (Fig. 3). The freedom from restenosis at
hree and eight months was 93% and 61% with stent use
nd 67% and 28% without stent use, respectively. A similar
egree of improvement was noted with the use of a
igher-dose AP immunosuppressant agent (Fig. 4). In the
roup using higher dose APs, there was a 88% and 60%
reedom from restenosis at three and eight months com-
ared with 70% and 30% in the lower or no AP dose group.
n “era effect” on the risk of restenosis was apparent after
997 (Fig. 5). In the post-1997 group, there was a 97% and
0% freedom from restenosis at three and eight months
ompared with 64% and 30% before 1997.
The interactions between risk factors are depicted in
igure 6. The predicted freedom from restenosis for a
atient undergoing a PCI after 1997 without a stent and on
lower dose or no AP immunosuppressant was 80% and
6% at three and eight months, respectively. When a
igher-dose AP was utilized, the freedom from restenosis
ncreases to 94% and 71% at three and eight months,
espectively. If a stent is added, a similar effect is noted with
93% and 67% freedom from restenosis at three and eight
onths, respectively. The most striking effect was noted
hen both a stent and a higher-dose AP were used in the
odern era of PCI. The freedom from restenosis with this
ombination was 98% at three months and 90% at eight
ention (PCI) for the 219 angioplasties. The parametric hazard model is
0%. The number of vessels still at risk of re-PCI is noted at the bottominterv
are 7onths.
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PTCA and Allograft Vasculopathy June 2, 2004:1973–81ra differences. In an attempt to understand this promi-
ent era effect, multiple patient-related procedural and
linical variables were compared in patients undergoing a
CI before and after 1997 (Table 3). There were no
ignificant patient-related differences. However, there were
any notable differences in procedural and clinical variables
etween these two eras. Subsequent to 1997, there was a
maller degree of residual stenosis after procedure (22% vs.
%, p  0.001), a higher pre-, post-MLD difference (50%
s. 65%, p  0.001), as well as a significantly greater use of
hienopyridines and glycoprotein IIb/IIIa antagonist use. In
ddition, there were several significant clinical changes
etween these two eras. In the post-1997 era, there was a
reater use of Neoral brand of cyclosporine and HMG-CoA
eductase inhibitors and less use of Cytoxan and calcium
hannel blockers. In addition, cyclosporine levels and tri-
lyceride levels were significantly lower in the post-1997
igure 2. Kaplan-Meier depiction of the event restenosis for the 219 angio
lotted (survival and hazard) as the smooth curve. Error bars and parame
s noted at the bottom of the plot. PCI  percutaneous coronary interve
able 2. Multivariate Predictors of Restenosis for PCI of
llograft Coronary Disease
Risk Factors for Restenosis Relative Risk p Value
se of stent 3.3 0.0001
igh dose antiproliferative* 1.9 0.0001
CI before 1997 2.6 0.0002
Stenosis pre-PCI† 2.3 0.0012
Azathioprine 1 mg/kg/day or mycophenolate 3 g/day; †relative risk for 90% vs.
0% pre-PCI stenosis.dPCI  percutaneous coronary intervention.ra. It should be noted, however, that none of these variables
ere individually identified as risk factors for restenosis
Table 2).
vent-free survival analyses. Twenty-five deaths occurred
n this series of patients, of which eight (32%) were related
o ACD. In addition, there were 10 re-transplants all due to
dvanced CAD. The freedom from death or retransplanta-
ion was 71% at one year and 34% at five years after
ntervention. This event rate was then stratified by number
f diseased vessels. The freedom from death or graft loss was
7%, 75%, and 74% at two years in patients with three-,
wo-, and one-vessel disease, respectively. At five years, the
reedom from death or graft loss was 0%, 42%, and 64% in
atients with three-, two-, and one-vessel disease,
espectively.
ISCUSSION
his analysis represents the largest reported experience of
CIs in cardiac transplant recipients to date. This study
upports the contention that PTCA with stents is effective
n relieving focal stenoses in patients with ACD. Initial
rocedural success is high with low periprocedural mortal-
ty. The risk of both restenosis and repeat PTCA is highest
n the first six months after therapy. The use of stents,
igher dose AP immunosuppressants, and modern proce-
ies (only 174 had follow-up angiograms). The parametric hazard model is
onfidence limits are 70%. The number of vessels still at risk of restenosis
.plast
tric cural techniques have markedly improved the initial result
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June 2, 2004:1973–81 PTCA and Allograft Vasculopathynd reduced the incidence of restenosis. The combination of
tents and higher-dose immunosuppressants in the post-
997 era led to a clinically important freedom from reste-
igure 3. Kaplan-Meier depiction of the event restenosis for the 219 angio
ars are 70%. The number still at risk at selected time points is indicated
igure 4. Kaplan-Meier depiction of the event restenosis for the 219 an
nti-proliferatives (AP). Error bars are 70%. The number still at risk at selected timeosis of 90% by six months. In several smaller studies of
ardiac transplant recipients undergoing PCIs, a cumulative
f 83 patients underwent PTCA without stenting and
ies (only 174 had follow-up angiograms) stratified by use of a stent. Error
rentheses. PCI  percutaneous coronary intervention.
sties (only 174 had follow-up angiograms) stratified by use of high-doseplastgiopla
points is indicated in parentheses. PCI percutaneous coronary intervention.
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PTCA and Allograft Vasculopathy June 2, 2004:1973–81emonstrated restenosis rates of 14% to 61% at four to seven
onths (7–9,12–14) In addition, one multicenter study of
5 patients undergoing PTCA of 95 lesions demonstrated a
5% restenosis rate at seven months. In several later studies
n patients undergoing PTCA alone, the restenosis rate at
wo to six months ranged from 67% to 100% (10,15,16).
nfortunately, in many of these studies, the definitions for
estenosis and the duration of follow-up differed, resulting
n considerable variability in the restenosis rate. However, it
s clear that the restenosis rates are generally higher than
eported for native-vessel CAD.
The use of stents has greatly impacted the success of
TCA in the treatment of native-vessel CAD with reduc-
ion of procedural complications and improvement in late
linical outcomes (17). The beneficial effects of stenting
ompared with PTCA at six months are related to a
eduction in restenosis rate by 30% and the need for surgical
evascularization by 50% (18). Restenosis after PTCA
esults from arterial remodeling and late vessel contraction
hat accounts for 60% of late lumen loss (19), both of
hich may be favorably affected by stenting.
Our analysis is in concert with available studies in heart
ransplant recipients examining the benefit of PTCA with
tenting in which restenosis rates at 6 to 12 months are
onsistently lower with the addition of stents (10,15,16).
e found a significant reduction in the freedom from
estenosis both early and late after PTCA with nearly a 50%
igure 5. Kaplan-Meier depiction of the event restenosis for the 219 angio
ercutaneous coronary intervention (PCI) was done. Error bars are 70%.eduction in restenosis at eight months. In addition, similar co the small series on stenting for ACD reported by
eublein and Jain (5,6), there were no incidences of acute
tent thrombosis. In light of this, we recommend routine
se of stents during PTCA for transplant patients with
ignificant focal ACD and appropriate anatomy for such a
rocedure.
One of the most interesting findings of this study was the
mproved procedural outcome for PCIs performed after
997, a finding also noted in the literature on native-vessel
CI. Registries of PCIs for native-vessel CAD clearly
emonstrate a stepwise improvement in the in-hospital
linical success rates from 82% in the mid-1980s, to 88% in
he early 1990s, to 92% in the late 1990s (20–22). The
estenosis rate also decreased from 38% in the early 1990s to
3% in the late 1990s. This trend is also noted for PCIs of
ocal ACD with improved restenosis rates of up to 25% in
he late 1990s (5).
There have been many procedural and nonprocedural
hanges in PCI and post-PCI care over the past 10 years,
hich may cumulatively explain this notable improvement
n procedural outcome. The multivariable model did not
dentify specific era-related variables (other than the era
tself) that were predictive of improved restenosis rates, but
everal factors may have contributed. It appears that the
pecific reduction in restenosis paralleled the achievement of
arger post-PCI lesion MLD, especially if the residual
tenosis was 20% (23–25). An increase of mean postpro-
ies (only 174 had follow-up angiograms) stratified by the era in which the
number still at risk at selected time points is indicated in parentheses.plastedural MLD from 1.67 mm in the early 1990s to 2.89 mm
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June 2, 2004:1973–81 PTCA and Allograft Vasculopathyn the late 1990s is clearly documented in the native CAD
iterature. Such was also the case in our series of PCIs in
ardiac transplant recipients with the achievement of larger
LDs in the modern era. It appears that this more
avorable procedural success seems to parallel the more
requent use of coronary stents, but may also be due to other
actors like higher inflation pressures during the interven-
ion (26–28).
In addition to these procedural advances, the introduction
nd widespread use of periprocedural glycoprotein IIb/IIIa
29) and thienopyridines (30) might also contribute to this
ra effect. The greater use HMG-CoA reductase inhibitors
nd lower triglyceride levels in our study in the post-1997
ra could be important because higher triglyceride levels are
ssociated with ACD (31) and with adverse vascular remod-
ling. HMG-CoA reductase inhibitors are vasoprotective,
oth in their ability to favorably affect lipids and inhibit
mooth muscle cell activity (32). In addition, they appear to
igure 6. Parametric prediction from the three-phase hazard model with 70
s set at 70%, and the era is set at 1997 or later. The curves represent the pre
se of stent (yes/no) and high-dose anti-proliferatives (AP) (yes/no).
able 3. The Era Effect on PCI of Allograft Coronary Disease
Procedural Variables Clinical Variables
ost-PCI stenosis less Neoral/cellcept use increased
re/post differences greater Cytoxan use decreased
tent use increased Cyclosporine A levels lower
Triglyceride levels lower
Statin use increased
Calcium channel blocker use decreased
Ticlid/plavix/GP IIb/IIIa use increasedtP  glycoprotein; PCI  percutaneous coronary intervention.e immunomodulatory, which could also theoretically lead
o a reduction in restenosis rates, by altering endothelial
ctivity and smooth muscles cell hyperactivity (33,34).
linically, the HMG-CoA reductase inhibitor pravastatin,
tarted within two weeks of transplantation, is associated
ith a lower incidence of ACD at angiography and autopsy
35).
The most interesting and novel immunosuppressant find-
ng from this study, however, is the reduction in restenosis
oted with higher doses of AP agents such as azathioprine
nd MMF. Although a preliminary and post-hoc finding,
he effect of these agents on restenosis is intriguing. In
ddition to its and T-cell and B-cell effects, MMF also can
nhibit growth factor-induced smooth muscle proliferation
36), which is a critical component of restenosis, particularly
fter stenting (37). In a study of heart transplant recipients,
hose patients receiving MMF had a significantly lower rate
n intimal proliferation compared with azathioprine (38). In
ddition, in a rabbit model of atherosclerosis, the adminis-
ration of MMF significantly reduced neointimal smooth
uscle cell accumulation and plaque development (39).
hus, one of the mechanisms by which MMF may ame-
iorate the development of restenosis after stenting is
hrough its actions on smooth muscle cell movement and
roliferation. The specific mechanism for the presumed
rotective effect of azathioprine is less apparent.
tudy limitations. As noted in prior studies on this topic,
fidence limits. The pre-percutaneous coronary intervention (PCI) stenosis
d probability of restenosis for all combinations of the remaining risk factors% con
dictehe influences generated by this study must be viewed with
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PTCA and Allograft Vasculopathy June 2, 2004:1973–81he realization that it is retrospective in nature, uncon-
rolled, and the result of a single institution’s experience.
his study is also confounded by the inherent complexity of
AD in the transplanted heart. Although the focus of this
tudy was PCIs as a therapy for ACD, only patients who
ctually underwent PCI were included in the analysis. The
arge “denominator” of patients with ACD includes many
atients not treated by PCI, who were not part of this
nalysis. Patients undergoing PCI for ACD form a heter-
geneous group among transplant institutions, in that con-
iderable differences exist for selection of patients and
ngiographic lesions for this procedure. Thus, inferences
rom this study may not be generally applicable to the whole
eart transplant community.
Allograft coronary disease is a life-long threat to heart
ransplant recipients and will require multiple avenues of
herapy to suppress or treat the multitude of contributing
actors. Percutaneous transluminal coronary angioplasty
ith stenting will only be of lasting therapeutic value if the
romising outcomes of the most favorable groups are
ustained over years. The eight-month follow-up is too
hort to gain meaningful insights into two- and three-year
utcomes. The impact of higher-dose azathioprine or
MF therapy (perhaps reflecting the value of AP agents) is
ntriguing, but it must be remembered that this dosing data
as collected at the time of PTCA intervention and does
ot necessarily reflect the overall or average AP dose since
ransplant or before the development of ACD.
However, the present study provides an element of
ational hope that such interventions could have an impor-
ant impact on certain aspects of this crippling post-
ransplant malady.
eprint requests and correspondence: Dr. Raymond L. Benza,
ivision of Cardiovascular Disease, Department of Medicine,
niversity of Alabama at Birmingham, 328A THT, 1900 Univer-
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